On the other hand, our research group was the first to develop SOCS3 peptidomimetics following a structure-based approach quite similar to that of SOCS1: a long peptide, called KIRESS, exhibited a good affinity for JAK2 and an efficient suppression of IL-22 signaling in keratinocytes, in athymic nude mice with squamous cell carcinoma (SCC) (83) as well as in primary tumour growth and pulmonary metastasis in triple negative breast cancer (TNBC) models (84). Here, SOCS3 is linked to triple-negative breast carcinoma.